CHBRP generally analyzes introduced bills prior to their first Senate or Assembly Health Committee hearing. Completed CHBRP analyses (and the analyzed bill language) are available at http://chbrp.org/analysis/completed-analyses. As bills move through the Legislature, bills may be significantly amended, which may alter CHBRP’s projected impacts. The table, below, indicates the final version of each analyzed bill and the extent to which CHBRP’s analyses remain relevant. Final bill language and the bill status are available at http://leginfo.legislature.ca.gov/.

CHBRP’s analyses may still be of use after the legislative cycle concludes in order to inform future legislation, the implementation of analyzed legislation that is signed into law or included in California’s budget, and the ongoing evaluation of relevant health benefit mandates and repeals.

The below is current as of 5/08/2023. 

Bill Bill amended since CHBRP analysis? Which portions of CHBRP’s analysis remain relevant?
AB 85
(Weber): Social Determinants of Health: Screening and Outreach
 Yes – 5/18/2023 All portions of CHBRP’s analysis remain relevant. Amended language expands which health care professionals health plans/policies are required to provide information about access to, and could lead to more enrollees gaining access to these professionals and receiving services they otherwise would not have.
AB 620
(Connolly): Metabolic Disorders
 Yes – 4/27/2023 All portions of CHBRP’s analysis remain relevant.
AB 716
(Boerner Horvath): Emergency Ground Medical Transportation
 Yes – 5/02/2023 All portions of CHBRP’s analysis remain relevant.
AB 874
(Weber): Out-of-pocket Expenses
 No All portions of CHBRP’s analysis remain relevant.
AB 907
(Lowenthal): Coverage for PANDAS and PANS
No All portions of CHBRP’s analysis remain relevant.
AB 1048
(Wicks): Dental Benefits and Rate Review
 Yes – 5/02/2023 All portions of CHBRP’s analysis remain relevant.
AB 1060
(Ortega): Naloxone Hydrochloride
 No All portions of CHBRP’s analysis remain relevant.
AB 1157
(Ortega): Rehabilitative and Habilitative Services: Durable Medical Equipment and Services
 No All portions of CHBRP’s analysis remain relevant.
AB 1288
(Reyes): Medication-Assisted Treatment
 No All portions of CHBRP’s analysis remain relevant.
AB 1451
(Jackson): Behavioral Health Crisis Treatment
 Yes – 5/18/2023 All portions of CHBRP’s analysis remain relevant.
AB 1645
(Zbur): Cost Sharing
 Yes – 5/01/2023 Amended language requires reimbursement of nonparticipating essential community providers at either the plan/insurer’s average contracted rate or 125% of the amount Medicare reimburses, whichever is greater. The inclusion of the rate related to Medicare and the requirement of using whichever is greater would result in some increased reimbursements, which would increase the impact on total expenditures from $20,065,000 to $23,237,000. All other portions of CHBRP’s analysis remain relevant.
SB 70
(Wiener): Prescription Drug Coverage
 Yes – 4/18/2023 All portions of CHBRP’s analysis remain relevant.
SB 90
(Wiener): Insulin Affordability
Yes– 5/01/2023 Amended language delays implementation in the small group and individual markets until 2025. All portions of CHBRP’s analysis remain relevant.
SB 339
(Wiener): HIV Preexposure Prophylaxis and Postexposure Prophylaxis
 No All portions of CHBRP’s analysis remain relevant.
SB 427
(Portantino): Antiretroviral Drugs, Devices, and Products
 No All portions of CHBRP’s analysis remain relevant.
SB 621
(Caballero): Biosimilar Drugs
 Yes – 5/02/2023 All portions of CHBRP’s analysis remain relevant.
SB 694
(Eggman) Medi-Cal: Self-Measured Blood Pressure Devices and Services
 No All portions of CHBRP’s analysis remain relevant.
SB 729
(Menjivar): Treatment for Infertility and Fertility Services
 Yes – 5/18/2023 Amended language would require coverage of fertility services for large group plans and policies, and would require small group and individual market plans and policies to offer coverage for fertility services. Scenario 2 remains relevant.